Samrat Pharmachem reported a net loss of Rs 3.31 crore for FY 2025-26, down from a profit of Rs 7.11 crore in the previous year. The company cited operational pressures leading to negative EBITDA, resulting in no dividend declaration for the year. Shareholders should note that the company faced a minor regulatory penalty for a delayed annual report filing. While revenue grew marginally to Rs 289.72 crore, management must now focus on cost-optimization to restore margins in the coming quarters.
Samrat Pharmachem Reports Rs 3.31 Crore Net Loss for FY26
Revenue grew marginally to Rs 289.72 crore; Net loss reached Rs 3.31 crore against previous profit of Rs 7.11 crore.
Reader Takeaway: Export growth provides a glimmer of hope, but operational losses and negative EBITDA demand immediate cost-control focus.
What just happened
Samrat Pharmachem has released its financial results for the fiscal year ended March 31, 2026. The company moved into a net loss of Rs 3.31 crore, a significant reversal from the Rs 7.11 crore profit recorded in the previous year. EBITDA turned negative at Rs 1.31 crore, reflecting severe margin pressure despite a marginal 1% rise in revenue from operations to Rs 289.72 crore.
Why this matters
The financial downturn has led the Board to skip dividend payments for the year, directly impacting shareholder returns. The company is also navigating minor regulatory friction, having paid a Rs 2,000 fine for a delayed annual report filing. These metrics highlight the operational challenges currently facing the business.
Operations and Business Update
Export performance remains a bright spot, with FOB sales rising to Rs 6.90 crore from Rs 5.75 crore. The company continued capital investment, spending Rs 6.29 crore on capex during the year. The upcoming Annual General Meeting is scheduled for September 23, 2026, where shareholders will vote on the re-appointment of Director Megh Mehta and the appointment of new statutory auditors, M/s. Divyesh J Shah & Associates.
Risks to watch
Investors should closely track the company's ability to return to profitability. The negative EBITDA suggests that the current cost structure is unsustainable. Additionally, compliance history regarding filing timelines will be a key area for shareholders to monitor in future quarters.
What to track next
Watch for management's strategy on cost-optimization and whether the current export growth trajectory can be scaled to offset rising operational expenses. The outcome of the upcoming AGM will provide further insight into the long-term governance and strategic direction.